Results 141 to 150 of about 10,701 (213)

CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder. [PDF]

Neuropsychopharmacology
Paslawski W, Doyon D, Ekman CJ, Yngwe H, Mamula D, Zareba-Paslawska J, Beckman M, Xu ZD, Hökfelt T, Tiger M, Lundberg J, Svenningsson P.   +11 more
europepmc   +1 more source

Learnings from a hybrid communities of practice group therapy model to support psilocybin-assisted therapy for patients with a terminal diagnosis. [PDF]

Front Public Health
Tsang VW, Kryskow P, Watler C, Allard P, Dames S.   +4 more
europepmc   +1 more source

Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial. [PDF]

Commun Med (Lond)
Armstrong SB, Levin AW, Sepeda ND, Shaub H, Hunter T, Douglas A, Lancelotta R, Davis AK.   +7 more
europepmc   +1 more source

Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits. [PDF]

Hum Brain Mapp
Pasquini L, Vohryzek J, Escrichs A, Perl YS, Ponce-Alvarez A, Idesis S, Girn M, Roseman L, Mitchell JM, Gazzaley A, Kringelbach M, Nutt DJ, Lyons T, Carhart-Harris RL, Deco G.   +14 more
europepmc   +1 more source